Trump unveils phased tariffs on generic drugs to reshore pharmaceutical manufacturing

Published Jul 22, 03:31 AM UTC

President Donald Trump announced a phased tariff regime on imported generic drugs, aiming to incentivize pharmaceutical companies to shift production to the United States. Announced via Truth Social on July 21, the policy grants a two-year tariff-free window starting August 1, 2026, followed by a 100% tariff in August 2028 and a 200% tariff thereafter for non-compliant importers. This extends earlier April 2026 actions under Section 232 that imposed tariffs on patented drugs and APIs, with generics initially exempted. The policy has significant implications for India, which supplies nearly 50% of US generic medicines by volume. Major Indian firms such as Sun Pharmaceutical, Dr. Reddy's, Cipla, Lupin, and Aurobindo Pharma face long-term pressure, though some have already expanded US manufacturing. Upstream reliance on Chinese APIs adds further vulnerability.